German science and technology company Merck lowered mid-term targets for its Life Sciences and Healthcare businesses, ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

Merck's new products have mitigated the generic competition, offsetting the recent major patent losses. In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar ...

Merck & Co., Inc. (MRK), headquartered in Rahway, New Jersey, is a major player in healthcare. Specializing in ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

In the past few months, Merck has discontinued trials that tested a Keytruda combination in skin or lung cancer. The trial for colorectal cancer enrolled 441 patients, where the participants who ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Merck & Co.'s stock was flat on Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of ...

Keytruda succeeds n a Phase 3 trial for head and neck cancer, showing promising results for event-free survival, the study's ...

Jefferies analyst Brian Balchin maintained a Buy rating on Merck KGaA (0O14 – Research Report) today and set a price target of €180.00.